Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Parsons wins $73M contract, totaling $218M for AFRL GARDEM digital platform support.

Market News
09 Jun 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Parsons Corporation secured an additional $73 million contract for the Air Force Research Laboratory’s GARDEM mission, bringing its total 2026 awards to $218 million. This contract expands Parsons' role in research, development, and maintenance of GARDEM 2 software platforms, including migrating capabilities to its Lightweight Application Management Platform (LAMP). The deal highlights Parsons' strength in delivering scalable, cost-effective digital solutions for the U.S. Air Force, enhancing mission readiness and operational efficiency. Parsons continues to build its portfolio in AI, data, cyber, and mission engineering to support national security missions.

More News

Hamanasi Resort in Belize named #1 hotel in Central America and #15 worldwide by Tripadvisor in 2026.

Hamanasi Resort in Belize named #1 hotel in Central America and #15 worldwide by Tripadvisor in 2026.

Hamanasi Adventure & Dive Resort in Belize was ranked the #1 hotel in Central America and #15 globally in the 2026 Tripadvisor Travelers’ Choice Best of the Best Awards. This prestigious recognition is based on exceptional guest reviews and highlight...

Others
Neutral
1 hour ago
US government buys 10% stake in mining firms, signaling a new strategic investment trend.

US government buys 10% stake in mining firms, signaling a new strategic investment trend.

In early 2026, the US government began acquiring stakes in American mining companies, including a 10% share in USA Rare Earth to support critical mineral projects. This move follows similar investments in Lithium Americas and Trilogy Metals, which sa...

Market News
Bullish
1 hour ago
FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.

FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.

The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...

Market News
Bullish
2 hours ago
FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.

FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.

The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process c...

Market News
Bullish
2 hours ago
Heartland Express declares $0.02 quarterly dividend, continuing 92 quarters of payouts.

Heartland Express declares $0.02 quarterly dividend, continuing 92 quarters of payouts.

Heartland Express, Inc. announced a regular quarterly cash dividend of $0.02 per share, payable on July 6, 2026, to shareholders of record as of June 23, 2026. This marks the company's 92nd consecutive quarterly dividend, with a total payout of $564....

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App